Tags

Type your tag names separated by a space and hit enter

Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients.
Ophthalmology 2005; 112(2):262-6O

Abstract

OBJECTIVE

To evaluate latanoprost versus bimatoprost given each evening over the 24-hour diurnal curve.

DESIGN

Double-masked, 2-center, crossover comparison.

PARTICIPANTS

Forty-two of 44 patients with primary open-angle glaucoma (POAG) completed the study.

METHODS

Consecutive patients were not treated during a baseline 24-hour curve after a glaucoma medicine-free period. They then were randomized to either latanoprost or bimatoprost for a 7-week treatment period. Diurnal curve intraocular pressures (IOPs) were measured at treatment period end at 2 am, 6 am, 10 am, 2 pm, 6 pm, and 10 pm. After the first treatment period, patients were changed to the opposite medicine without a medicine-free period. Diurnal curve measurements were performed again at the end of the second 7-week treatment period.

MAIN OUTCOME MEASURE

The 24-hour diurnal IOP.

RESULTS

On the last day of treatment, mean 24-hour IOPs were 17.3+/-2.8 mmHg for latanoprost and 16.7+/-2.4 mmHg for bimatoprost (P = 0.01). The 6 pm individual time point for IOP was statistically lower for bimatoprost after a Bonferroni correction (P = 0.008). The largest IOP difference at any time point was 0.9 mmHg at 6 pm. The most common side effect was conjunctival hyperemia, which occurred less with latanoprost (n = 6) than with bimatoprost (n = 15) (P = 0.004). Two patients had their treatments discontinued while on bimatoprost, one due to conjunctival hyperemia and the other due to ocular intolerance.

CONCLUSION

This study indicates that the 24-hour diurnal IOP is statistically lower in POAG with bimatoprost, compared with latanoprost, among patients who tolerated bimatoprost. However, the IOP difference between groups was small and may not be clinically meaningful. In contrast, conjunctival hyperemia seems statistically greater with bimatoprost. The exact clinical importance of conjunctival hyperemia, if any, needs to be clarified further.

Authors+Show Affiliations

Glaucoma Unit, University Department of Ophthalmology, AHEPA Hospital, Thessaloniki, Greece.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

15691561

Citation

Konstas, Anastasios G P., et al. "Latanoprost 0.005% Versus Bimatoprost 0.03% in Primary Open-angle Glaucoma Patients." Ophthalmology, vol. 112, no. 2, 2005, pp. 262-6.
Konstas AG, Katsimbris JM, Lallos N, et al. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112(2):262-6.
Konstas, A. G., Katsimbris, J. M., Lallos, N., Boukaras, G. P., Jenkins, J. N., & Stewart, W. C. (2005). Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology, 112(2), pp. 262-6.
Konstas AG, et al. Latanoprost 0.005% Versus Bimatoprost 0.03% in Primary Open-angle Glaucoma Patients. Ophthalmology. 2005;112(2):262-6. PubMed PMID: 15691561.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. AU - Konstas,Anastasios G P, AU - Katsimbris,John M, AU - Lallos,Nikolaos, AU - Boukaras,George P, AU - Jenkins,Jessica N, AU - Stewart,William C, PY - 2004/06/04/received PY - 2004/08/27/accepted PY - 2005/2/5/pubmed PY - 2005/2/17/medline PY - 2005/2/5/entrez SP - 262 EP - 6 JF - Ophthalmology JO - Ophthalmology VL - 112 IS - 2 N2 - OBJECTIVE: To evaluate latanoprost versus bimatoprost given each evening over the 24-hour diurnal curve. DESIGN: Double-masked, 2-center, crossover comparison. PARTICIPANTS: Forty-two of 44 patients with primary open-angle glaucoma (POAG) completed the study. METHODS: Consecutive patients were not treated during a baseline 24-hour curve after a glaucoma medicine-free period. They then were randomized to either latanoprost or bimatoprost for a 7-week treatment period. Diurnal curve intraocular pressures (IOPs) were measured at treatment period end at 2 am, 6 am, 10 am, 2 pm, 6 pm, and 10 pm. After the first treatment period, patients were changed to the opposite medicine without a medicine-free period. Diurnal curve measurements were performed again at the end of the second 7-week treatment period. MAIN OUTCOME MEASURE: The 24-hour diurnal IOP. RESULTS: On the last day of treatment, mean 24-hour IOPs were 17.3+/-2.8 mmHg for latanoprost and 16.7+/-2.4 mmHg for bimatoprost (P = 0.01). The 6 pm individual time point for IOP was statistically lower for bimatoprost after a Bonferroni correction (P = 0.008). The largest IOP difference at any time point was 0.9 mmHg at 6 pm. The most common side effect was conjunctival hyperemia, which occurred less with latanoprost (n = 6) than with bimatoprost (n = 15) (P = 0.004). Two patients had their treatments discontinued while on bimatoprost, one due to conjunctival hyperemia and the other due to ocular intolerance. CONCLUSION: This study indicates that the 24-hour diurnal IOP is statistically lower in POAG with bimatoprost, compared with latanoprost, among patients who tolerated bimatoprost. However, the IOP difference between groups was small and may not be clinically meaningful. In contrast, conjunctival hyperemia seems statistically greater with bimatoprost. The exact clinical importance of conjunctival hyperemia, if any, needs to be clarified further. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/15691561/Latanoprost_0_005_versus_bimatoprost_0_03_in_primary_open_angle_glaucoma_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(04)01469-1 DB - PRIME DP - Unbound Medicine ER -